Personal information

No personal information available

Activities

Employment (4)

St Vincent's Hospital: Melbourne, Victoria, AU

2013 to present | Head of Dermatology Research (Dermatology)
Employment
Source: Self-asserted source
PETER FOLEY

Probity Medical Research: Waterloo, Ontario, CA

2010 to present | Associate Investigator
Employment
Source: Self-asserted source
PETER FOLEY

Skin Health Institute: Carlton (Melbourne), Victoria, AU

2008 to present | Director of Research
Employment
Source: Self-asserted source
PETER FOLEY

The University of Melbourne: Melbourne, Victoria, AU

1998 to present | Associate Professor (Medicine)
Employment
Source: Self-asserted source
PETER FOLEY

Education and qualifications (1)

Australasian College of Dermatologists: Boronia Park, NSW, AU

1998 to present | Fellow
Qualification
Source: Self-asserted source
PETER FOLEY

Professional activities (1)

Skin Health Institute: Carlton, Victoria, AU

2021 | Members' Special Recognition Award
Distinction
Source: Self-asserted source
PETER FOLEY

Works (19)

Asia‐Pacific consensus recommendations on the management of generalized pustular psoriasis

The Journal of Dermatology
2024-12 | Journal article
Contributors: Siew Eng Choon; Peter Anthony Foley; Pravit Asawanonda; Hideki Fujita; Seong‐Jin Jo; Yu‐ling Shi; Colin Theng; Azura Mohd Affandi; Chul Hwan Bang; Maria Lorna Frez et al.
Source: check_circle
Crossref

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Journal of Dermatological Treatment
2024-12-31 | Journal article
Contributors: Neil J. Korman; Richard B. Warren; Jerry Bagel; April W. Armstrong; Melinda Gooderham; Bruce Strober; Diamant Thaçi; Akimichi Morita; Shinichi Imafuku; Peter Foley et al.
Source: check_circle
Crossref

Efficacy and Safety of Switching From Intravenous to Subcutaneous Infliximab for Psoriasis: A Case Series

Australasian Journal of Dermatology
2024-12-31 | Journal article
Contributors: Conor Larney; Peter Foley; Kurt Gebauer; Benjamin S. Daniel
Source: check_circle
Crossref

Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Considerations for paediatric patients

Australasian Journal of Dermatology
2024-09 | Journal article
Contributors: Peter Foley; Patrick D. Mahar; Saxon D. Smith; Monisha Gupta; Nicholas Manuelpillai; David Orchard; Li‐Chuen Wong; John C. Su; Amelia James; Gayle Fischer et al.
Source: check_circle
Crossref

Barriers to the introduction of novel advanced targeted treatments for Australian dermatology patients: Are skin diseases symptomatic of a systemic healthcare problem?

Australasian Journal of Dermatology
2024-09 | Journal article
Contributors: Patrick David Mahar; Anna Crothers; Peter Foley; Joseph Thomas
Source: check_circle
Crossref

Pityriasis rosea-like drug eruption secondary to deucravacitinib

JAAD Case Reports
2024-09 | Journal article
Contributors: Nisal Punchihewa; Senhong Lee; Chin-Guan Tan; Peter Foley
Source: check_circle
Crossref

Tildrakizumab use for recalcitrant pityriasis rubra pilaris

Australasian Journal of Dermatology
2024-08 | Journal article
Contributors: Zachary Holmes; Michelle S. Goh; Peter Foley; Benjamin S. Daniel
Source: check_circle
Crossref

Paediatric indications and dosing guidance for advanced targeted treatments in Australia

Australasian Journal of Dermatology
2024-06 | Journal article
Contributors: Patrick D Mahar; Susan J Robertson; David Orchard; Christopher Baker; Peter Foley
Source: check_circle
Crossref

Pharmaceutical Management of Rosacea—An Australian/New Zealand Medical Dermatology Consensus Narrative

Dermatologic Therapy
2024-01 | Journal article
Contributors: M. Rademaker; P. Foley; J. Sullivan; K. Armour; C. Baker; A. Ferguson; K. Gebauer; M. Gupta; G. Marshman; E. McMeniman et al.
Source: check_circle
Crossref

Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients

Australasian Journal of Dermatology
2023-11 | Journal article
Contributors: Peter Foley; Kurt Gebauer; John Sullivan; Erin McMeniman; Stephen Shumack; Jonathan Ng; Amelia James; Morton Rawlin; Shireen Sidhu; Dev Tilakaratne et al.
Source: check_circle
Crossref

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study

British Journal of Dermatology
2023-08-10 | Journal article
Contributors: Joseph F Merola; Albert S Chiou; Emmanuel During; Antonio Costanzo; Peter Foley; Amani Alfalasi; Shaila Gogate; Andreas Pinter; Roni Dodiuk-Gad; Dagmar Simon et al.
Source: check_circle
Crossref

Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting

Australasian Journal of Dermatology
2022-11 | Journal article
Contributors: Peter Foley; Yves A. Kerdraon; John P. Hogden; Stephen Shumack; Lynda Spelman; Deshan F. Sebaratnam; Charles S. Su; Constance H. Katelaris
Source: check_circle
Crossref

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)

Australasian Journal of Dermatology
2022-08 | Journal article
Contributors: Peter Foley; Nick Manuelpillai; Con Dolianitis; Geoffrey D. Cains; Eric Mate; Rebecca Tronnberg; Christopher Baker
Source: check_circle
Crossref

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*

British Journal of Dermatology
2021-12 | Journal article
Contributors: K. Reich; K. B. Gordon; B. E. Strober; A. W. Armstrong; M. Miller; Y. K. Shen; Y. You; C. Han; Y. W. Yang; P. Foley et al.
Source: check_circle
Crossref

Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital

Dermatologic Therapy
2021-11 | Journal article
Contributors: Sarah Ringin; Christopher S. Baker; Peter Foley; Benjamin S. Daniel
Source: check_circle
Crossref

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Dermatology and Therapy
2021-08-18 | Journal article
Contributors: Christopher Griffiths; Marjolein de Bruin-Weller; Mette Deleuran; Maria Concetta Fargnoli; Delphine Staumont-Sallé; Chih-ho Hong; Jose Sánchez-Carazo; Peter Foley; Seong Jun Seo; Jérôme Msihid et al.
Source: check_circle
Crossref

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

American Journal of Clinical Dermatology
2020-12-10 | Journal article
Contributors: Kristian Reich; April W. Armstrong; Peter Foley; Michael Song; Megan Miller; Y. K. Shen; Yin You; Chenglong Han; Kenneth B. Gordon
Source: check_circle
Crossref

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

Journal of Dermatological Treatment
2020-08-17 | Journal article
Contributors: Kristian Reich; Peter Foley; Chenglong Han; Sean McElligott; Erik Muser; Nan Li; April W. Armstrong
Source: check_circle
Crossref

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Dermatology and Therapy
2020-06-21 | Journal article
Contributors: Craig Leonardi; Kristian Reich; Peter Foley; Hideshi Torii; Sascha Gerdes; Lyn Guenther; Melinda Gooderham; Laura K. Ferris; Christopher E. M. Griffiths; Hany ElMaraghy et al.
Source: check_circle
Crossref